Advertisement
Advertisement
CTOR
C
Citius Oncology, Inc. Common Stock
0.91
USDSponsored
+0.01
+0.65%
May 08, 15:58 UTC -4
Closed
After-Market
0.90
-0.01
-0.97%
CTOR Earnings Reports
Positive Surprise Ratio
CTOR beat 2 of 5 last estimates.
40%
Next Report
Date of Next Report
May 20, 2026
Estimate for Q2 26 (Revenue/ EPS)
$7.14M
/-$0.01
Implied change from Q1 26 (Revenue/ EPS)
+81.14%
/-83.33%
Implied change from Q2 25 (Revenue/ EPS)
--
/-90.91%
Citius Oncology, Inc. Common Stock earnings per share and revenue
On Feb 13, 2026, CTOR reported earnings of -0.06 USD per share (EPS) for Q1 26, missing the estimate of 0.06 USD, resulting in a -198.04% surprise. Revenue reached 3.94 million, compared to an expected 4.46 million, with a -11.67% difference. The market reacted with a +3.39% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 3 analysts forecast an EPS of -0.01 USD, with revenue projected to reach 7.14 million USD, implying an decrease of -83.33% EPS, and increase of 81.14% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
ANI Pharmaceuticals, Inc.
Report Date
May 08, 2026 For Q1 26
Estimate
$1.33
Actual
$2.04
Surprise
+54.04%
Harmony Biosciences Holdings, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
$0.72
Actual
$0.55
Surprise
-24.16%
CytomX Therapeutics, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.12
Actual
-$0.10
Surprise
+18.83%
Tectonic Therapeutic, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.20
Actual
-$1.34
Surprise
-11.07%
ALX Oncology Holdings Inc. Common Stock
Report Date
May 08, 2026 For Q1 26
Estimate
-$0.22
Actual
-$0.17
Surprise
+24.24%
Entera Bio Ltd. Ordinary Shares
Report Date
May 08, 2026 For Q1 26
Estimate
-$0.15
Actual
-$0.07
Surprise
+54.25%
argenx SE - ADR
Report Date
May 07, 2026 For Q1 26
Estimate
$5.47
Actual
$5.52
Surprise
+0.86%
Arrowhead Research Corporation
Report Date
May 07, 2026 For Q2 26
Estimate
-$1.16
Actual
-$0.93
Surprise
+20.32%
ImmunityBio, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.07
Actual
-$0.09
Surprise
-26.05%
Stoke Therapeutics, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.84
Actual
-$0.79
Surprise
+6.34%
FAQ
What were Citius Oncology, Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Citius Oncology, Inc. Common Stock reported EPS of -$0.06, missing estimates by -198.04%, and revenue of $3.94M, -11.67% below expectations.
How did the market react to Citius Oncology, Inc. Common Stock's Q1 2026 earnings?
The stock price moved up 3.39%, changed from $1.18 before the earnings release to $1.22 the day after.
When is Citius Oncology, Inc. Common Stock expected to report next?
The next earning report is scheduled for May 20, 2026.
What are the forecasts for Citius Oncology, Inc. Common Stock's next earnings report?
Based on 3
analysts, Citius Oncology, Inc. Common Stock is expected to report EPS of -$0.01 and revenue of $7.14M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement